181 related articles for article (PubMed ID: 34152569)
1. The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.
Albano D; Dondi F; Zilioli V; Panarotto MB; Galani A; Cappelli C; Bertagna F; Giubbini R; Casella C
Ann Nucl Med; 2021 Oct; 35(10):1089-1099. PubMed ID: 34152569
[TBL] [Abstract][Full Text] [Related]
2. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
3. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
5. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
6. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
7. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
Claimon A; Pusuwan P; Khiewvan B
J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
[TBL] [Abstract][Full Text] [Related]
8. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
9. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
10. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma.
Wang J; Mao Y; Li L; Liang J; Huang H; Lin W; Chen G; Wen J
Endocrine; 2024 May; ():. PubMed ID: 38809346
[TBL] [Abstract][Full Text] [Related]
12. Avidity and Outcomes of Radioiodine Therapy for Distant Metastasis of Distinct Types of Differentiated Thyroid Cancer.
Simões-Pereira J; Mourinho N; Ferreira TC; Limbert E; Cavaco BM; Leite V
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3911-e3922. PubMed ID: 34134139
[TBL] [Abstract][Full Text] [Related]
13. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.
Slonimsky E; Tulchinsky M
Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402
[TBL] [Abstract][Full Text] [Related]
14. Effect of Hashimoto thyroiditis on low-dose radioactive-iodine remnant ablation.
Kwon H; Choi JY; Moon JH; Park HJ; Lee WW; Lee KE
Head Neck; 2016 Apr; 38 Suppl 1():E730-5. PubMed ID: 25899980
[TBL] [Abstract][Full Text] [Related]
15. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
[TBL] [Abstract][Full Text] [Related]
19. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer.
Albano D; Panarotto MB; Durmo R; Rodella C; Bertagna F; Giubbini R
Endocrine; 2019 Jan; 63(1):79-86. PubMed ID: 30112608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]